N. Anthony Coles
Known title: DirectorCIK: 0001197018
Associated companies
Transaction History
| REGN | ▲ Buy | Grant | 155 | $0 | 1/2/2026 | View on chart |
| REGN | ▲ Buy | Grant | 166 | $0 | 1/2/2025 | View on chart |
| REGN | ▲ Buy | Grant | 135 | $0 | 1/2/2024 | View on chart |
| REGN | ▲ Buy | Grant | 165 | $0 | 1/3/2023 | View on chart |
| REGN | ▲ Buy | Option Exercise | 2,145 | $802K | 12/28/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 679 | $483K | 12/28/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 311 | $223K | 12/28/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 181 | $128K | 12/28/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 2,266 | $1.6M | 12/28/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 3,613 | $1.7M | 12/28/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 100 | $71K | 12/28/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 1,198 | $855K | 12/28/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 1,022 | $730K | 12/28/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 1 | $710 | 12/28/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 2,216 | $829K | 9/6/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 300 | $173K | 9/6/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 3,784 | $1.4M | 9/6/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 500 | $289K | 9/6/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 273 | $158K | 9/6/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 550 | $319K | 9/6/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 688 | $399K | 9/6/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 822 | $478K | 9/6/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 1,220 | $711K | 9/6/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 1,045 | $609K | 9/6/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 602 | $352K | 9/6/2022 | View on chart |
| REGN | ▲ Buy | Grant | 191 | $0 | 1/3/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 300 | $198K | 9/15/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 448 | $296K | 9/15/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 3,344 | $2.2M | 9/15/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 3 | $2K | 9/15/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 1,174 | $780K | 9/15/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 905 | $601K | 9/15/2021 | View on chart |
| REGN | ▲ Buy | Option Exercise | 6,909 | $2.6M | 9/15/2021 | View on chart |
| REGN | ▲ Buy | Option Exercise | 5,039 | $1.7M | 9/15/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 300 | $195K | 9/15/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 1,101 | $719K | 9/15/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 800 | $523K | 9/15/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 403 | $264K | 9/15/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 1,400 | $919K | 9/15/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 835 | $549K | 9/15/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 935 | $616K | 9/15/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 5,100 | $3.3M | 8/18/2021 | View on chart |
| REGN | ▲ Buy | Option Exercise | 5,100 | $1.8M | 8/18/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 900 | $585K | 8/17/2021 | View on chart |
| REGN | ▲ Buy | Option Exercise | 900 | $311K | 8/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock
Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock. Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.